First-in-class Cancer Immunotherapy Drug in Clinical TrialA small molecule has entered a novel clinical trial for cancer immunotherapy. The molecule inhibits an enzyme called MALT1 that plays a critical role in suppressing immune reactions against tumor cells. Preclinical studies showed that blocking MALT1 activity results in immune reactivation and boosts an anti-tumor immune response.
Children and Corona: Study detects more infections than reported cases during the second wave in GermanyA study by Helmholtz Zentrum München concludes that during the second Corona wave, three to four times more children in Bavaria, Germany were infected with the Corona virus than reported via PCR tests.
New Study on SARS-CoV-2A new study uncovers which cell types can be infected by SARS-CoV-2 due to their viral entry factors. The study also suggests that increased gene expression of these viral entry factors in some individuals partially explains the differences of COVID-19 severity reported in relation to age, gender and smoking status.
Coronavirus Update
Due to the ongoing coronavirus pandemic, some precautions are being taken on the premises of Helmholtz Zentrum München to protect employees from infection and to contain the spread of the coronavirus. All measures are constantly being reviewed. Further information on the current regulations and our contribution to the fight against the pandemic can be found by following the link below.
Focus
Helmholtz Zentrum München by numbers
Research fingerprint
Translate
Discovery that addresses real world problems and offers tangible medical solutions.
Science and Society
We actively involve the general public, to disseminate and raise awareness about the current state of research. Learn more about our services.
Distinguished national programs
Sustainable research
Graduate Program and Research Schools
The Helmholtz Graduate School Environmental Health (HELENA) develops the next generation of internationally competitive researchers.
